6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: Design, synthesis and in vitro evaluation.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Medicinal chemistry

• Publication date

  2017-05-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1573406413666170109142725PMID 28067167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Morphology‐Specific Inhibition of β‐Amyloid Aggregates by 17β‐Hydroxysteroid Dehydrogenase Type 10

  2016cited by this paper
• Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.

  2016cited by this paper
• Excited-State Proton Transfer Can Tune the Color of Protein Fluorescent Markers.

  2015cited by this paper
• Benzothiazoles - scaffold of interest for CNS targeted drugs.

  2015cited by this paper
• Ligand-based 3D QSAR analysis of reactivation potency of mono- and bis-pyridinium aldoximes toward VX-inhibited rat acetylcholinesterase.

  2015cited by this paper
• 6-Hydroxyquinolinium salts differing in the length of alkyl side-chain: synthesis and antimicrobial activity.

  2014cited by this paper
• Identification of human ABAD inhibitors for rescuing Aβ-mediated mitochondrial dysfunction.

  2014cited by this paper
• 99Tc NMR as a promising technique for structural investigation of biomolecules: theoretical studies on the solvent and thermal effects of phenylbenzothiazole complex

  2014cited by this paper
• Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.

  2012cited by this paper
• Open3DALIGN: an open-source software aimed at unsupervised ligand alignment

  2011cited by this paper
• Inhibition of the Mitochondrial Enzyme ABAD Restores the Amyloid-β-Mediated Deregulation of Estradiol

  2011cited by this paper
• Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

  2010cited by this paper
• N‐Benzylsalicylthioamides: Highly Active Potential Antituberculotics

  2009cited by this paper
• QSAR analysis of salicylamide isosteres with the use of quantum chemical molecular descriptors.

  2009cited by this paper
• Pharao: pharmacophore alignment and optimization.

  2008cited by this paper
• Identification of small-molecule inhibitors of the Abeta-ABAD interaction.

  2006cited by this paper
• Roles of type 10 17beta-hydroxysteroid dehydrogenase in intracrinology and metabolism of isoleucine and fatty acids.

  2006cited by this paper
• Medicinal chemical properties of successful central nervous system drugs

  2005cited by this paper
• Type 10 17beta-hydroxysteroid dehydrogenase catalyzing the oxidation of steroid modulators of gamma-aminobutyric acid type A receptors.

  2005cited by this paper
• Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics.

  2004cited by this paper
• Alignment of three-dimensional molecules using an image recognition algorithm.

  2004cited by this paper
• Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B

  2003cited by this paper
• A comparison of physiochemical property profiles of development and marketed oral drugs.

  2003cited by this paper
• Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model.

  2002cited by this paper
• Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability*

  2002cited by this paper
• Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes.

  2002cited by this paper
• Intraneuronal Abeta42 accumulation in human brain.

  2000cited by this paper
• Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT.

  2000cited by this paper
• Translating cell biology into therapeutic advances in Alzheimer's disease

  1999cited by this paper
• Role of ERAB/l-3-Hydroxyacyl-coenzyme A Dehydrogenase Type II Activity in Aβ-induced Cytotoxicity*

  1999cited by this paper
• Mutant genes in familial Alzheimer's disease and transgenic models.

  1998cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• Chance factors in studies of quantitative structure-activity relationships.

  1979cited by this paper

• High-Throughput Screening of Potent Drug-like Molecules Targeting 17β-HSD10 for the Treatment of Alzheimer’s Disease and Cancer

  2025cites this paper
• Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases

  2025cites this paper
• Synthesis and biological characterization of a 17β hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitor.

  2024cites this paper
• Sulfonyl thioureas with a benzo[d]thiazole ring as dual acetylcholinesterase/butyrylcholinesterase and human monoamine oxidase A and B inhibitors: An in vitro and in silico study

  2024cites this paper
• C-3 Steroidal Hemiesters as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 10

  2024cites this paper
• Design, Synthesis and Biological Activities of (Thio)Urea Benzothiazole Derivatives

  2023cites this paper
• Development of submicromolar 17β-HSD10 inhibitors and their in vitro and in vivo evaluation.

  2023cites this paper
• Physiologically relevant fluorescent assay for identification of 17β‐hydroxysteroid dehydrogenase type 10 inhibitors

  2023influential citation
• Frentizole derivatives with mTOR inhibiting and senomorphic properties.

  2023cites this paper
• Nanomolar Benzothiazole-Based Inhibitors of 17β-HSD10 with Cellular Bioactivity.

  2023cites this paper
• Regulation of beta‐amyloid for the treatment of Alzheimer's disease: Research progress of therapeutic strategies and bioactive compounds

  2023cites this paper
• Infantile Neurodegeneration Results from Mutants of 17β-Hydroxysteroid Dehydrogenase Type 10 Rather Than Aβ-Binding Alcohol Dehydrogenase

  2023cites this paper
• Synthesis and Biological Importance of 2-(thio)ureabenzothiazoles

  2022cites this paper
• The Role of a Pathological Interaction between β-amyloid and Mitochondria in the Occurrence and Development of Alzheimer’s Disease

  2022cites this paper
• Virtual screening and molecular dynamic study of potential new binders to mTOR

  2022cites this paper
• Sulfur-containing therapeutics in the treatment of Alzheimer’s disease

  2021cites this paper
• Benzothiazolyl Ureas are Low Micromolar and Uncompetitive Inhibitors of 17β-HSD10 with Implications to Alzheimer’s Disease Treatment

  2020cites this paper
• SEARCHING FOR NEW ANTIMICROBIAL AGENTS BY TARGETING BACTERIAL NAD METABOLISM: EVALUATION OF FRENTIZOLE DERIVATIVES SELECTED BY MOLECULAR DOCKING

  2020cites this paper
• Friend or enemy? Review of 17β‐HSD10 and its role in human health or disease

  2020cites this paper
• Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency.

  2020cites this paper
• Effects of novel 17β-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration.

  2020cites this paper
• Novel Benzothiazole-Based Ureas as 17β-HSD10 Inhibitors, A Potential Alzheimer’s Disease Treatment

  2019cites this paper
• Mitochondrial dysfunction and Alzheimer’s disease: prospects for therapeutic intervention

  2019cites this paper
• Identification of steroidal derivatives inhibiting the transformations of allopregnanolone and estradiol by 17β-hydroxysteroid dehydrogenase type 10.

  2018cites this paper
• Amyloid-Binding Alcohol Dehydrogenase (ABAD) Inhibitors for the Treatment of Alzheimer's Disease.

  2018cites this paper
• Structure Confirmation and Evaluation of a Nonsteroidal Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type 10

  2018cites this paper
• Benzothiazole-Based Therapeutics: FDA Insights and Clinical Advances

  year unknowninfluential citation